Home › Research › Getting a diagnosis
Impact of multiple pathologies on the threshold for clinically overt dementia
Kapasi A, DeCarli C, Schneider JA.. Acta neuropathologica, 2017-05-09
Topic: Risk, prevention and care in population studies
Longitudinal clinical-pathological studies have increasingly recognized the importance of mixed pathologies (the coexistence of one or more neurodegenerative and cerebrovascular disease pathologies) as important factors in the development of Alzheimer's disease (AD) and other forms of dementia. Older persons with AD pathology, often have concomitant cerebrovascular disease pathologies (macroinfarcts, microinfarcts, atherosclerosis, arteriolosclerosis, cerebral amyloid angiopathy) as well as other concomitant neurodegenerative disease pathologies (Lewy bodies, TDP-43, hippocampal sclerosis). These additional pathologies lower the threshold for clinical diagnosis of AD. Many of these findings from pathologic studies, especially for CVD, have been confirmed using sophisticated neuroimaging technologies. In vivo biomarker studies are necessary to provide an understanding of specific pathologic contributions and time course relationships along the spectrum of accumulating pathologies. In this review, we provide a clinical-pathological perspective on the role of multiple brain pathologies in dementia followed by a review of the available clinical and biomarker data on some of the mixed pathologies.
Key findings
- Many of these findings from pathologic studies, especially for CVD, have been confirmed using sophisticated neuroimaging technologies.
Why it matters
This review describes how the coexistence of multiple brain pathologies, such as Alzheimer's disease pathology together with cerebrovascular or other neurodegenerative pathologies, lowers the threshold for clinically overt dementia. It is a clinical-pathological perspective and reports no treatment, cure or prevention.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 66/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Acta neuropathologica) |
| Journal's citation record | 3 / 4 | Acta Neuropathologica: journal h-index 287 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 740 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 67.3 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 5 / 6 | Cited 35.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 84 other studies in this library |
| Still being cited | 4 / 4 | Cited 304 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Julie A. Schneider: h-index 151 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of California, Davis: institution h-index 1,257 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 28488154) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 66 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Kapasi, A., DeCarli, C., & Schneider, J. A. (2017). Impact of multiple pathologies on the threshold for clinically overt dementia. Acta neuropathologica. https://doi.org/10.1007/s00401-017-1717-7
Vancouver
Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta neuropathologica. 2017. doi:10.1007/s00401-017-1717-7. PMID: 28488154.
BibTeX
@article{kapasi2017-28488154,
author = {Kapasi, A. and DeCarli, C. and Schneider, J. A.},
title = {{Impact of multiple pathologies on the threshold for clinically overt dementia}},
journal = {Acta neuropathologica},
year = {2017},
doi = {10.1007/s00401-017-1717-7},
pmid = {28488154},
url = {https://doi.org/10.1007/s00401-017-1717-7}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 65.
Later studies that cite this one
84 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.